Human Immunodeficiency Virus Pre-exposure Prophylaxis | Disease Landscape & Forecast | G7 | 2022
Pre-exposure prophylaxis (PrEP) is a key prevention strategy for ending the human immunodeficiency virus (HIV) epidemic. The FDA’s approval of Gilead’s Truvada in 2012 and Descovy in 2019 provided the first two PrEP options for HIV prevention in individuals who are HIV-negative but at risk of sexually acquired HIV-1 infection. The FDA’s approval of ViiV’s Apretude (cabotegravir) in December 2021 will provide an additional option and enable preferential prescribing to the HIV PrEP-eligible population. In addition, many late-phase PrEP therapies, such as Gilead’s lenacapavir and Merck’s islatravir, are expected to offer less-frequent dosing, as well as improved safety, to become key differentiating attributes in HIV prevention. The HIV PrEP market will continue to grow owing to the launch of generic versions of Truvada, increasing initiatives by the government and companies to provide free PrEP drugs, and growing awareness of PrEP that will lead to an increase in the target population. In this report, we explore the clinical and commercial potential of approved and emerging HIV PrEP therapies.
Questions answered
- How large is the HIV PrEP-eligible population in the United States, EU5, and Japan? How will the population change over the forecast period?
- What is the current market landscape for HIV PrEP? How will HIV PrEP emerging therapies like lenacapavir and islatravir compete with Apretude and other entrenched brands like Descovy and Truvada?
- What are the healthcare policies that will influence access and reimbursement of HIV PrEP therapies, and how much of an impact will these strategies have?
- What are the most promising agents in the HIV PrEP pipeline, and how will they be differentiated from current therapies? What sales / uptake could emerging therapies secure during the forecast period?
GEOGRAPHIES
United States, EU5, Japan
PRIMARY RESEARCH
17 country-specific interviews with thought-leading infectious disease and internal medicine physicians
Supported by survey data collected for this and other Clarivate research
EPIDEMIOLOGY
Number of PrEP-eligible populations by country
FORECAST
10-year, annualized, drug-level sales and patient share of key HIV PrEP therapies through 2031, segmented by brands / generics
EMERGING THERAPIES
Phase III / PR / Approved: 12 drugs; coverage of select early-phase products
Marketed drugs: 3
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
